drugset / Trial / NCT01750398

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy.

Timeline

Start
2013-01
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Cypionate Small molecule 400 mg Intramuscular
Background Goserelin Other / unclassified Intramuscular
Background Leuprolide Other / unclassified Intramuscular

Indications